We kill cancer. Selectively.
With our unique technology, we can kill cancer cells without affecting healthy cells. We treat cancer with minimal side effects, using Lumoxbodies and light.
WHAT DO WE DO ?
At Lumox, we developed a potent anticancer therapy with minimal side effects. Achieving this level of safety is attributed to two levels of selectivity:
-
Lumoxbodies: Crafted from nanobodies, Lumoxbodies serve as targeting tools, guiding light-activatable drugs directly to cancer cells.
- Local Activation: The therapy uses local drug activation by exposing the Lumoxbodies at the tumor site to light.
This innovative approach has undergone extensive validation in preclinical models and is currently undergoing successful experimentation in the veterinary clinic. The results are promising, showcasing robust antitumor activity coupled with a notable absence of side effects.
WHO ARE WE ?
Lumox is proud to be an Utrecht University spin-off company, derived from the group of Associate Professor Sabrina Oliveira. With our technology, we want to cure cancer patients without side effects. The first indication in which we will demonstrate our technology is head and neck cancer.
· The Technology ·
Head and Neck Cancer
· How It Works ·
1.
Lumoxbodies bind to cancer cells
2.
Light locally activates bound Lumoxbodies
3.
Lumoxbodies destroy cancer cells
· Core Team ·
Irati Beltrán Hernández
Studied Biotechnology at the Autonomous University of Barcelona and obtained her PhD at Utrecht University in Sabrina Oliveira’s group, on the topic of Lumoxbodies for anticancer therapy. She then stayed in the group as a postdoctoral researcher and has been working on the development of this therapy towards the clinic for over 7 years now.
